12. Congenital myasthenic syndrome Clinical trials / Disease details
Clinical trials : 5 / Drugs : 7 - (DrugBank : 3) / Drug target genes : 5 - Drug target pathways : 13
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02189720 (ClinicalTrials.gov) | July 2014 | 5/7/2014 | Expanded Access Study Amifampridine Phosphate in Congenital Myasthenic Syndrome (CMS) | An Open-Label, Expanded Access Protocol for Amifampridine Phosphate Treatment in Patients With Congenital Myasthenic Syndrome (CMS) | Congenital Myasthenic Syndrome | Drug: Amifampridine Phosphate | Catalyst Pharmaceuticals, Inc. | NULL | No longer available | 2 Years | N/A | All | United States |